Asian Companies Are Building a New Industrial Footprint Across Germany

Germany’s industrial and logistics property market is gaining a new group of occupiers. Asian companies, particularly businesses connected to Chinese e-commerce and distribution networks, are taking a growing amount of warehouse and industrial space as they establish larger operations inside Europe. The shift is becoming large enough to influence Germany’s principal logistics markets. During the first half of 2026, Asian occupiers accounted for approximately 11% of industrial and logistics take-up nationally. Their presence was considerably greater in some cities, reaching around 24% in Cologne, 11% in Düsseldorf and 9% in Hamburg.

Several of the largest German industrial transactions completed during the period involved Asian companies, including facilities of more than 50,000 square metres. The numbers indicate that what was previously a relatively small source of international occupier demand is becoming a meaningful component of the market. For property investors and developers, however, the more important question is what happens next.

The current expansion is being led mainly by distribution, logistics and online retail rather than by a wave of new Asian factories. But the warehouses appearing today could represent the first stage of a much deeper physical presence in Germany. Companies entering a new market typically establish distribution infrastructure before committing to manufacturing. Products are initially imported, stored locally and delivered to customers. As sales increase, businesses add spare-parts operations, technical support, repair centres, product preparation and regional management. Assembly and manufacturing can follow once the European business reaches sufficient scale.

Germany is particularly well positioned for this progression. It is Europe’s largest consumer economy, sits at the centre of the continent’s transport network and borders nine countries. A distribution centre in western or central Germany can serve not only German customers but also markets across Benelux, France, Austria, Switzerland, Poland and the Czech Republic.

Germany also offers something especially important to Asian industrial companies: an enormous manufacturing ecosystem. Its automotive, machinery, electronics and chemical industries have created extensive networks of engineers, component suppliers, industrial contractors and logistics providers. Companies entering Europe do not therefore need to construct an entire supply chain from the beginning.

This could become particularly relevant for Chinese electric-vehicle manufacturers. Chinese automotive groups are increasing their European presence as they compete for market share with established European manufacturers. While Germany has not yet experienced a broad wave of Chinese vehicle factories, expanding sales will require more physical infrastructure.

Imported vehicles need storage, preparation and distribution. Dealers require spare parts. Customers need servicing. Batteries need specialist handling and replacement, while software and electronic systems require technical support. Each of those activities consumes property. A company can therefore build a substantial German industrial footprint without manufacturing a complete vehicle in the country.

Initially, this demand is likely to appear through vehicle logistics centres, parts warehouses, technical facilities, repair operations and regional offices. Over time, some of these operations could evolve into component assembly or production.

Battery businesses could follow a similar path. Battery manufacturing itself requires specialised facilities and very large amounts of power, making it difficult to place in conventional logistics buildings. But the battery supply chain includes many less specialised functions, including storage, testing, recycling, servicing, component distribution and engineering. These activities can occupy industrial properties that sit somewhere between a warehouse and a factory.

Electronics companies create similar requirements. Businesses selling telecommunications equipment, consumer electronics, energy systems and industrial technology increasingly need European inventories together with facilities for testing, configuration, repair and technical support. This could increase demand for modern light-industrial property.

Instead of a conventional warehouse containing little more than storage racks, developers may increasingly encounter international occupiers requiring a mixture of distribution, workshop, laboratory, office and assembly space within the same building. That has implications for how future industrial parks are designed. Greater electricity capacity may be necessary. Buildings may need larger office or technical areas, stronger floors, more flexible loading arrangements and the ability to divide space between storage and production.

Developers that understand these requirements could gain an advantage as Asian occupiers expand. The geography of demand is already providing clues. Cologne and Düsseldorf are benefiting from access to Germany’s largest population concentration and excellent motorway connections toward Belgium and the Netherlands. The wider Rhine-Ruhr region also provides access to inland ports and established logistics infrastructure.

Hamburg offers another strategic gateway because of its port and long-standing trading connections with Asia. Frankfurt combines one of Europe’s largest airfreight hubs with a central location on Germany’s motorway network, allowing goods to reach a large portion of the country’s population within a relatively short period. These characteristics help explain why Asian occupiers are becoming increasingly visible in these markets.

But their search is starting to extend beyond Germany’s traditional logistics centres. Limited availability in established markets is forcing some international companies to consider secondary locations. Chinese occupiers that initially concentrated heavily on North Rhine-Westphalia are increasingly examining opportunities elsewhere.

That could benefit cities located along major motorway corridors outside the country’s most expensive logistics markets. For developers controlling suitable land in those areas, Asian demand could provide an additional source of occupiers.

The opportunity may be particularly significant where projects can be delivered quickly. International companies establishing European operations frequently work with shorter expansion timetables than Germany’s planning system comfortably accommodates. An occupier may decide that it requires a distribution facility within months, while obtaining planning approval and constructing a completely new building can take several years.

Sites where planning and infrastructure are already established therefore become more valuable. This could connect Asian occupier growth with another important change occurring in German industrial property: the increasing reuse of former manufacturing land.

Automotive restructuring and changes across traditional German manufacturing could release factories and industrial sites during the coming years. Many already contain electricity connections, loading infrastructure, offices and access to skilled workers. These properties could be attractive to Asian businesses seeking rapid entry into Germany.

A former automotive supplier facility, for example, could potentially accommodate an electronics company, vehicle-parts distributor or light manufacturer with substantially less preparation than undeveloped land. This creates an unusual interaction between Germany’s old and new industrial economies.

Some Asian companies are competing directly with German manufacturers in global markets, particularly in electric vehicles and electronics. At the same time, those companies could become future tenants or buyers of industrial properties released by German businesses undergoing restructuring. The companies challenging parts of Germany’s manufacturing economy may therefore also help create demand for its industrial real estate.

Brownfield redevelopment could accelerate this process. Developers acquiring former factories could reposition them for international occupiers by creating combinations of logistics, light manufacturing and technical space. Sites with existing power capacity and established industrial planning could be particularly attractive.

Build-to-suit development may also become more important. The current shortage of suitable logistics space means some occupiers cannot find buildings matching their requirements in their preferred locations. If Asian companies continue expanding, developers may increasingly construct facilities specifically for them rather than waiting for suitable existing buildings to become available.

Such projects could range from conventional distribution centres to hybrid properties combining warehousing, assembly and technical operations. For investors, however, this creates a different underwriting challenge.

Many Asian businesses are major companies in their domestic markets but have relatively short European operating histories. Their German subsidiaries may have been established only recently and therefore provide less financial information than traditional German occupiers. Institutional landlords may consequently require stronger guarantees, larger deposits or support from parent companies before committing to long leases.

This could create opportunities for developers willing to accept more leasing risk. A developer could secure an international occupier, construct or refurbish the property and establish several years of rental history before selling the stabilised asset to institutional capital.

The ability to design flexible buildings will be particularly important. A highly specialised property created for one occupier can become difficult to re-let if that company later changes strategy. Developers should therefore attempt to accommodate technical requirements without making buildings unusable for future logistics or manufacturing tenants.

That distinction becomes increasingly important as Asian demand moves beyond warehousing. A conventional distribution centre can generally be occupied by another logistics company. A customised vehicle assembly or battery facility has a much smaller pool of replacement users. Investors will therefore need to balance the attraction of long leases with the future adaptability of the property.

The broader German logistics market provides a supportive backdrop for this expansion. Industrial and logistics take-up strengthened during the first half of 2026, with the major property advisers reporting increases compared with the previous year despite differences in their market definitions. Large transactions also returned after a relatively quiet period.

This matters because Asian demand is arriving in a market where suitable modern buildings are already limited in many locations. The result could be greater competition for well-positioned industrial sites.

Asian occupiers will not be the only companies seeking them. Logistics operators, German manufacturers, defence businesses, data-centre developers and energy-related companies are increasingly competing for similar land. Electricity capacity could become one of the deciding factors.

Modern e-commerce operations use increasingly sophisticated automation, while electronics, battery and advanced-manufacturing businesses require substantially greater power than traditional warehouses. A site with a large existing grid connection may therefore appeal to several different types of occupiers. This could push developers toward former industrial locations where substantial infrastructure already exists.

The long-term significance of Asian occupier growth consequently extends beyond the amount of warehouse space leased in 2026. Germany may be moving toward a different relationship with Asian industry.

Historically, much of the property impact of Asian trade was indirect. Goods arrived through ports and were handled by European logistics companies. Increasingly, Asian businesses are establishing their own operational infrastructure inside Europe. That means warehouses, offices, technical centres and potentially manufacturing facilities carrying the names of Asian companies rather than simply handling their products.

The transition could accelerate as supply chains become more regional. Companies facing tariffs, geopolitical uncertainty and changing European regulations have incentives to establish more operations inside the markets they serve. Local inventory reduces delivery times and supply-chain risk, while European assembly or production can potentially provide strategic advantages.

Germany will compete with Poland, Hungary, the Czech Republic and other European countries for these investments. It will not necessarily win every manufacturing project. Central and Eastern European markets can offer lower labour and land costs, while some governments provide aggressive incentives for large industrial investments.

Germany’s advantage lies elsewhere. Its enormous consumer market, established supplier networks, skilled engineering workforce and central location make it particularly attractive for European headquarters, distribution, servicing and higher-value manufacturing functions.

This could produce a network rather than a single concentration of Asian investment. Large distribution centres may locate in western Germany. Technical and engineering operations could favour established manufacturing regions. Port-related businesses may concentrate around Hamburg, while Central European supply chains could support locations farther east.

For industrial property developers, understanding these different requirements will become increasingly important. The occupier profile of Germany’s logistics market is changing.

Domestic manufacturers and traditional third-party logistics companies will remain important, but they are being joined by businesses whose European expansion strategies are being decided thousands of kilometres away. That introduces new sources of capital, demand and competition for industrial land.

It also creates uncertainty. International expansion can move rapidly in both directions. A company entering Germany aggressively may change strategy if trade policy, tariffs or European demand deteriorate. Developers therefore need to distinguish between short-term logistics requirements and companies building permanent European operations.

The most attractive occupiers will be those gradually adding functions to their German businesses. A company that begins with a warehouse and subsequently adds repair, engineering, assembly and management functions becomes much more deeply embedded in the market.

That progression will be one of the most important indicators to watch over the next several years. The question is therefore no longer simply how much German warehouse space Asian companies are leasing. It is whether Germany is becoming part of their permanent European operating infrastructure.

The first half of 2026 provides growing evidence that this process has begun. Asian companies already account for a meaningful share of German industrial and logistics demand, particularly in some of the country’s largest markets.

If the next stage brings technical operations, assembly and manufacturing alongside distribution, the consequences for commercial real estate could be substantial. Germany could find that one of the most important new sources of demand for its industrial property comes from companies that, until recently, mainly served the European market from the other side of the world.

Source: CIJ.World Research & Analysis Team

Japan Unlocks New Real Estate Value Along Its Urban Waterfronts

Japan’s waterfronts are entering another stage of transformation as cities reconsider how valuable land surrounding their ports can contribute to future urban growth. Areas once dominated by shipyards, cargo handling and industrial infrastructure are increasingly accommodating offices, hotels, homes, retail, entertainment, cultural facilities and public spaces.

The transition is particularly visible in Yokohama, Tokyo and Kobe, where decades of port restructuring have created opportunities to introduce new uses to strategically located waterfront land. Rather than abandoning their maritime economies, these cities have increasingly separated modern logistics operations from areas capable of supporting higher-value urban development.

This distinction is important for real estate. Container terminals and other large-scale port operations require extensive land, efficient road connections and facilities capable of handling increasingly large vessels. Older inner-harbour sites do not always provide the most efficient environment for these activities, particularly when they sit immediately beside established city centres.

Moving or reorganising some of these functions can release unusually large development sites in locations where comparable land would otherwise be extremely difficult to assemble.

Yokohama’s Minato Mirai 21 provides one of Japan’s most established examples of this process. Development of the approximately 186-hectare waterfront district began in the early 1980s on land previously associated with shipbuilding, freight and other port-related activities.

The objective went considerably further than redeveloping an obsolete industrial site. Yokohama used the project to connect previously separated sections of its central area while creating a new commercial and business district capable of strengthening the city’s economic position within Greater Tokyo.

Over subsequent decades, offices, hotels, residential towers, shopping destinations, cultural venues, convention facilities and public spaces were introduced alongside major transport improvements. Today, Minato Mirai functions as an extension of central Yokohama rather than a peripheral waterfront development.

Almost all of the planned development area has now been completed, is under construction or has been allocated for future use, demonstrating the extraordinary time horizon involved in regeneration at this scale.

For the property industry, Minato Mirai shows how infrastructure and public investment can transform the economics of former industrial land. New railway connections, roads, pedestrian routes and public spaces helped create the conditions for private commercial development, while the waterfront itself became part of the area’s attraction to businesses, residents and visitors.

Tokyo provides a different example because of the enormous scale of land created around its port.

Since the 1960s, approximately 2,766 hectares have been reclaimed within the Port of Tokyo. The land has accommodated a wide variety of uses, ranging from container terminals and essential infrastructure to parks, housing and commercial development.

Within this much larger reclaimed area, Tokyo Waterfront City covers approximately 442 hectares and demonstrates how newly created land can be incorporated into the wider metropolitan economy.

Districts including Odaiba, Ariake and Aomi have developed into locations for exhibitions, hotels, entertainment, offices, retail and residential uses while remaining closely connected with port and infrastructure functions elsewhere along Tokyo Bay.

The result is not a conventional redevelopment model in which industrial activity disappears entirely. Instead, Tokyo demonstrates how a working port and large-scale urban development can coexist by allocating different sections of the waterfront according to their most appropriate economic function.

This ability to create substantial new urban districts is particularly valuable in a city where large central development sites are scarce. As demand for modern commercial and residential property changes, reclaimed waterfront locations provide Tokyo with development capacity that would be extremely difficult to generate within established neighbourhoods.

Kobe is now offering another version of the same wider transformation.

The city’s identity has always been closely connected with its port, but changes in container shipping gradually altered the geography of freight activity. Modern cargo operations increasingly concentrated around Port Island and Rokko Island, allowing parts of the older waterfront closer to central Kobe to take on new roles.

Regeneration has gathered momentum over the past decade, with the city now planning another significant phase of development through its latest waterfront strategy.

The programme looks toward approximately 2040 and places greater emphasis on connecting the harbour with central Kobe, improving pedestrian movement, expanding green and public spaces and encouraging more activity after normal business hours. Private investment is expected to play an important role in introducing new commercial, leisure and tourism uses.

This creates opportunities across several property sectors.

Hotels can benefit from tourism and waterfront locations, while restaurants, entertainment venues and cultural facilities can extend the amount of time visitors spend in the area. Residential development can take advantage of attractive surroundings and proximity to the city centre, while carefully positioned offices can appeal to companies seeking locations outside traditional corporate districts.

The attraction of waterfront regeneration is also closely connected with scarcity. Large development sites close to established city centres are difficult to find in Japan, particularly in metropolitan markets where land ownership is highly fragmented.

Former industrial and port sites can provide something different: sufficient scale to create complete neighbourhoods rather than individual buildings.

That allows planners and developers to coordinate offices, housing, hospitality, leisure and public infrastructure from the beginning. It also creates opportunities to introduce parks, pedestrian routes and waterfront access that can increase the attractiveness of surrounding private development.

However, converting port land into urban property is neither simple nor inexpensive.

Waterfront sites require substantial infrastructure investment and careful management of environmental and natural-hazard risks. Flooding, storm surges, earthquakes and ground conditions can influence construction costs and development design. Former industrial locations may also require remediation before new uses can be introduced.

There can also be tension between property development and the continuing economic role of ports. Japan remains heavily dependent on maritime trade, meaning commercially attractive waterfront redevelopment cannot simply displace strategically important logistics infrastructure.

The strongest projects therefore depend on finding a balance.

Modern freight operations need to remain in locations capable of handling future logistics requirements, while older sites that are no longer essential to those operations can be opened to alternative investment.

This is what makes Japan’s waterfront story particularly relevant to real estate investors. The opportunity is not simply created by proximity to water. Value emerges when changes to infrastructure allow land to move from a relatively restricted industrial function toward a broader range of economically productive uses.

The process can take decades, as Yokohama demonstrates, but successful waterfront regeneration can permanently alter the investment geography of a city.

Tokyo continues to use reclaimed land to accommodate functions that would be difficult to deliver elsewhere. Kobe is entering another phase of harbour regeneration designed to attract private capital and reconnect the city with its waterfront. Yokohama provides evidence of what can ultimately be achieved when infrastructure, planning and commercial development are coordinated over the long term.

Together, the three cities demonstrate how Japan is gradually extracting greater urban value from one of its most important geographical assets.

The country’s ports will remain essential gateways for trade, but the land surrounding them is increasingly capable of serving a much wider purpose. As logistics infrastructure modernises and cities search for new development capacity, Japan’s waterfronts are becoming not only places of movement and commerce, but some of the country’s most significant long-term real estate opportunities.

Source: © CIJ.World Japan Research & Analysis Team

KeyBank Shows Where AI Is Starting to Deliver Measurable Value in Consumer Banking

Artificial intelligence in banking is moving beyond experimentation and into a more practical phase focused on operational value, customer intelligence and faster decision-making. At AI4 2026, a KeyBank executive responsible for consumer-bank AI strategy described how the institution is identifying the parts of its business where AI can produce the clearest commercial return, while avoiding the temptation to apply the technology everywhere at once. The presentation, “When the Rubber Meets the Road: How the Consumer Bank is Realizing Value With KeyBank,” focused less on model capabilities and more on where AI is actually changing day-to-day banking.

The central argument was that banks should begin with their core business functions and identify where intelligence, automation and better use of data can directly improve service, reduce friction or strengthen competitiveness. The presentation identified technology and operations as two of the most promising areas for AI deployment because these functions sit behind much of what determines whether a bank can serve customers quickly, understand their needs, process documents efficiently and respond to competitors.

One of the most important use cases is the long-standing ambition to create a complete view of the customer. Banks possess large amounts of transaction, deposit, lending and behavioural data, but assembling that information into a usable picture has historically been difficult. AI does not remove the need for clean and well-organised data, but it can accelerate the process of connecting that information and making it accessible to employees. A bank that understands how money moves through a customer’s accounts can identify changes in behaviour more quickly. If customers begin transferring significant funds away from the institution, for example, the bank can recognise the change sooner and determine whether there is a relationship issue, a competing financial product or another reason behind the movement.

The same intelligence can support what banks increasingly describe as the next best action. Instead of employees approaching customers with generic product offers, AI can potentially help bankers understand the circumstances surrounding each relationship and identify which conversation is most relevant at that moment. The objective is not simply selling more products but improving the timing and relevance of customer interactions. This moves customer analytics towards a more continuous model in which behaviour can be interpreted as it changes rather than relying entirely on broad and relatively static customer segments.

Document management represents another major opportunity because banking remains heavily dependent on paperwork. Regulatory disclosures, trust agreements, mortgage documentation, customer statements, internal policies and procedures create enormous quantities of information that employees must locate, interpret and process. AI can reduce the amount of time spent navigating that material. One example discussed involved trust documentation within wealth management, where multiple agreements can change over time and employees need to determine which document governs the current relationship. AI-powered search can help locate the appropriate material and surface the relevant clauses without requiring employees to work manually through large repositories.

Home lending provides another obvious application. Mortgage processes involve relatively standardised documentation but large volumes of information. AI can extract data, analyse documents and accelerate initial processing before a human makes or approves the final decision. This combination of machine processing and human oversight is particularly suited to banking, where automation can reduce administrative work without removing accountability from regulated decisions.

Internal procedure search is another comparatively straightforward but potentially valuable use case. Bank employees regularly need guidance on how to complete specific transactions or resolve unusual customer requests. Traditional keyword search may return numerous documents that employees still have to read before finding the correct procedure. Natural-language AI can narrow that search and provide the relevant information more directly, reducing the time spent navigating internal systems.

The presentation also highlighted competitive uses of document intelligence. Merchant-services teams, for example, may receive pricing statements from competing providers. AI can analyse those documents more quickly and help a bank generate an alternative proposal, shortening the time between an initial conversation and a competing offer. In this type of use case, the commercial benefit is not abstract productivity but the ability to respond to potential customers faster.

Data engineering is another less visible but potentially important area. Banks depend on large numbers of pipelines connecting customer information, financial systems, risk platforms and reporting tools. AI-assisted development can help engineers build and maintain those pipelines more quickly, improving the speed at which useful information becomes available to business teams.

Data visualisation could change as well. Large organisations have traditionally relied on dedicated business-intelligence platforms that require time to design and maintain dashboards. Generative AI makes it increasingly possible to create smaller, purpose-built web interfaces or visualisations rapidly, potentially allowing business teams to obtain precisely the information they need without commissioning large dashboard projects. This points towards a broader transformation in enterprise software in which employees increasingly create targeted applications around specific problems instead of adapting every task to large standardised systems.

KeyBank’s experience suggests this is already beginning informally. Employees are increasingly able to prototype applications themselves using AI coding tools. The challenge shifts from building the prototype to determining which applications are robust enough, secure enough and important enough to be placed into production across a regulated organisation. Modern AI makes creating software easier, but running production systems inside a bank still requires cybersecurity, data governance, testing, integration and ongoing maintenance. A useful tool developed for a small team is not automatically an enterprise application.

The same principle applies to broader AI deployment. Rather than building every solution centrally, the presentation described a layered approach in which some employees use generally available enterprise AI tools for everyday productivity, existing software vendors provide AI features within systems employees already know, and more complicated business problems are escalated to specialist teams developing custom solutions. This allows AI adoption to spread beyond the relatively small number of people working directly in machine learning or software engineering.

The productivity implications can become meaningful even when individual time savings appear small. The speaker used KeyBank’s workforce as an example, arguing that if every employee saved only one hour per week through AI tools, the cumulative effect across an organisation employing more than 17,000 people would be substantial. The example illustrates why large companies are concentrating increasingly on relatively simple productivity tools alongside more ambitious AI projects. A small improvement repeated thousands of times can have more financial impact than a sophisticated demonstration used by only a handful of employees.

However, the presentation repeatedly returned to the importance of solving actual business problems rather than developing technology for its own sake. The consumer-bank AI team has accumulated a large backlog of potential applications, but not every idea can or should be developed. The more effective approach is to begin with the operational problem and work backwards towards the technology. Banks increasingly need to ask whether an application reduces processing time, improves customer retention, increases conversion, lowers operating costs or reduces risk. If there is no clear answer, the project may have little commercial value regardless of how sophisticated the underlying model appears.

Adoption is closely related to the same issue. Employees are much more likely to use AI when the application solves something they already find frustrating. Forcing technology into a workflow without demonstrating a practical benefit creates resistance, while building around actual user problems makes adoption considerably easier.

The presentation also emphasised that successful AI deployment requires cooperation across an organisation. A specialist AI group cannot independently transform a bank. Technology teams, operations, risk departments, business leaders and senior executives all have to participate because each controls a different part of the process required to put applications into production. Executive alignment is particularly important because AI initiatives that remain isolated within individual teams may produce interesting prototypes but struggle to obtain the funding, permissions and organisational changes required for broader adoption.

External vendors form another part of the ecosystem. Banks increasingly rely on technology providers not only for products but also for information about emerging frameworks and capabilities. The challenge is balancing access to innovation with the need to maintain control over sensitive data, costs and technology architecture.

Governance therefore remains fundamental to the entire strategy. Not every AI system presents the same level of risk. An internal tool helping an employee summarise a document is different from a model influencing lending or interacting directly with customers. Banks consequently need governance structures that reflect the potential consequences of each application rather than treating every AI tool identically.

The handling of customer information is especially sensitive. During questions following the presentation, the KeyBank speaker said customer data used in AI development is tokenised and accessed through controlled internal data environments rather than exposing personally identifiable information directly inside development workflows. This was presented as part of the bank’s internal approach rather than a general industry standard.

This balance between experimentation and control will become increasingly important as AI spreads further through financial institutions. Banks hold some of the most sensitive data in the economy and operate within regulatory systems built around accountability, auditability and customer protection.

The broader lesson from KeyBank’s experience is therefore less about any single AI application than about the emerging operating model surrounding them. AI value is beginning to appear in practical areas such as understanding customer behaviour, finding documents, accelerating mortgage processing, improving internal search, building data pipelines and giving employees better productivity tools. None of these applications individually represents the futuristic autonomous bank frequently imagined in discussions about artificial intelligence.

Together, however, they could significantly change how a consumer bank operates. The most successful institutions may ultimately be those that resist the temptation to pursue AI everywhere and instead identify the relatively small number of problems where better intelligence or automation materially changes the customer experience or the economics of the business. For banking, the point at which AI becomes strategically important may therefore not be when customers begin talking to sophisticated digital financial advisers. It may arrive much earlier, when thousands of small decisions, searches, document reviews and operational tasks across the organisation quietly become faster and more intelligent.

Source: CIJ.World Research & Analysis Team

Africa’s Property Data Race Could Determine Where AI Delivers the Biggest Investment Advantage

Artificial intelligence is beginning to enter Africa’s property industry, but its most important impact may have less to do with automated marketing or replacing traditional brokers than with solving one of the continent’s longstanding investment problems: information. Reliable transaction evidence, ownership records, rental data, development pipelines and building-performance information remain uneven across African markets. As property technology develops, the countries that build the strongest digital foundations could become considerably easier for investors to analyse. This distinction matters because artificial intelligence does not create reliable property information by itself. It can process large quantities of information, identify patterns and accelerate analysis, but the quality of its conclusions ultimately depends on the information available to it. A sophisticated valuation system working with incomplete transaction records will still produce uncertain results, while the same technology operating in a market with extensive digital property records, reliable addresses and detailed historical transactions can become considerably more useful.

Africa could therefore develop an AI property divide in which the most important advantage belongs not necessarily to the countries adopting the largest number of new applications, but to those creating the best underlying property databases. South Africa currently has one of the strongest foundations for this transition. Its comparatively mature banking system, listed property sector, formal transaction market and established property-data industry provide substantially more information for automated analysis than is available in many other African countries. Property-data businesses such as Lightstone have already demonstrated how large collections of residential and property information can support automated valuation and risk analysis. These systems pre-date the recent explosion in generative AI and should not automatically be described as examples of the newest artificial-intelligence technology. Nevertheless, they illustrate an important principle: automated property analysis becomes considerably more powerful when it can draw on extensive historical information.

For investors, this can reduce the amount of time required to understand individual properties and surrounding markets. Comparable transactions can be identified more efficiently, neighbourhood patterns can be examined across larger datasets and unusual pricing or ownership characteristics can be highlighted for further investigation. The next development is likely to involve combining established property databases with newer analytical tools capable of processing both structured and unstructured information. An investor assessing an office acquisition, for example, may eventually be able to examine transactions, leases, operating expenses, planning information, environmental risks and surrounding development activity through a much more integrated analytical process. This does not eliminate professional valuation or due diligence. Instead, it changes where professionals spend their time, with less effort required to collect and organise information and more attention available for interpreting risks that automated systems cannot adequately understand.

Kenya presents a different opportunity because digitisation of land administration could eventually become as important as private-sector property technology. Digital land systems have the potential to reduce dependence on fragmented physical documentation and make ownership information easier to search and verify. This is particularly important for institutional investment. Before capital can evaluate a warehouse, office development or residential project, investors need confidence that ownership and development rights can be established reliably. Lengthy or uncertain title investigations increase transaction costs and can discourage investors from entering unfamiliar markets. Kenya’s continuing digitisation of land records therefore has implications beyond administrative convenience. A more complete digital property system could eventually provide the foundation for automated title searches, development analysis and more sophisticated property databases.

However, digitisation should not automatically be confused with artificial intelligence. Moving land records from paper into searchable databases is an important technological improvement, but it does not necessarily mean that AI is conducting the verification. Claims that AI alone has reduced Kenyan land-verification procedures from several weeks to less than two days require stronger evidence before they can be treated as a general market development. The distinction illustrates a wider problem with discussions about property technology. Database automation, digital cadastral systems, statistical valuation models, machine learning and generative AI are frequently grouped together even though they perform very different functions. For investors, the terminology matters less than whether the technology produces information that can be trusted.

Nigeria may provide one of the largest opportunities for improvement because the scale of its property market contrasts with the fragmented nature of information available across many locations. Lagos contains enormous volumes of residential and commercial development, yet obtaining reliable transaction evidence and verifying individual properties can remain considerably more complicated than in highly transparent global markets. This creates an unusual situation in which AI has both enormous potential and significant limitations. Technology can organise listings, analyse asking prices, identify development patterns and process large volumes of documents. But where actual transaction prices are unavailable, titles remain difficult to verify or listings contain inconsistent information, automated systems can reproduce those weaknesses rather than eliminate them.

Nigeria’s emerging property platforms can nevertheless contribute to gradual improvement. As more listings, searches, transactions and property characteristics are recorded digitally, larger datasets begin to form. Over time, these datasets could improve understanding of individual neighbourhoods and help developers identify where demand is strongest. For commercial real estate investors, the value could be particularly significant. Lagos contains numerous industrial, logistics, office, retail and residential submarkets whose performance can vary dramatically within relatively short distances. Better data analysis could make it easier to identify where rents are genuinely increasing, where new supply is accumulating and where infrastructure investment is changing development potential.

Fraud detection is another area where technology could help, although expectations should remain realistic. Automated systems can identify inconsistencies, duplicated information and unusual transaction patterns. They can also assist institutions in screening large numbers of records more efficiently. They cannot, however, solve defective land administration or unclear ownership structures by themselves. If the underlying registry is incomplete, an automated system cannot manufacture the missing legal certainty. The largest improvements in transaction security will therefore require technology to develop alongside stronger registries, administrative processes and legal enforcement.

Egypt offers another important test because Cairo combines a very large property development market with rapidly expanding new urban districts. Large masterplans, new office districts and extensive residential development generate significant quantities of information that could increasingly be used for development planning and asset management. Developers can potentially use more advanced analytics to assess sales patterns, pricing, customer demand and the performance of different phases within large projects. Commercial landlords can analyse occupier behaviour, building usage and energy consumption, while investors can process larger quantities of market information when evaluating acquisitions.

Building operations may ultimately become one of the most practical areas of AI adoption across African commercial property. Modern offices, shopping centres, hotels, logistics facilities and mixed-use developments increasingly generate information through building-management systems, access controls, energy meters and other connected equipment. Analysing that information can help landlords understand when buildings are being used, where electricity is being consumed and whether equipment is operating inefficiently. In markets where power is expensive or unreliable, even relatively modest improvements in energy management can have a direct financial impact. This could make the African business case for intelligent buildings different from that in some developed markets. Reducing energy consumption is not simply an environmental objective when electricity costs, backup generation and infrastructure reliability materially affect operating expenses. Technology capable of predicting demand or identifying inefficient equipment can become part of the property’s income-protection strategy.

The same principle applies to climate and physical risk. Large property portfolios contain assets exposed to different combinations of flooding, heat, water shortages and infrastructure stress. Automated analysis can potentially combine environmental information with individual asset locations to help investors identify where additional resilience expenditure may be required. Again, the quality of the result depends on the information being analysed. Accurate geospatial data and detailed building characteristics are essential if automated climate analysis is to influence investment decisions reliably.

Property finance represents another potentially significant application. Large parts of Africa have relatively shallow mortgage markets, while many households and smaller businesses have limited formal credit histories. Alternative data and automated credit analysis could eventually help financial institutions assess some borrowers more efficiently. That possibility should not be interpreted as evidence that AI alone will solve Africa’s housing-finance shortage. Mortgage affordability is also determined by interest rates, household income, property prices, loan duration and the availability of long-term funding. Technology can improve parts of the underwriting process without changing those fundamental economics.

The same caution applies to the suggestion that AI will eliminate informal property brokers. Digital platforms can automate listings, generate property descriptions, respond to enquiries and improve searches based on customer preferences. These functions may reduce some routine work, but African property transactions frequently depend on local knowledge, negotiation, physical inspections and relationships that remain difficult to automate. The more significant change may therefore occur within brokerage rather than through its disappearance. Agents equipped with better information and automated tools may be able to analyse more properties, respond to clients faster and spend less time on repetitive administrative work.

For institutional investors, however, the largest opportunity remains transparency. International property capital prefers markets where assets can be compared, ownership can be established, income can be verified and transactions can be completed predictably. When that information is difficult to obtain, investors require more due diligence, spend longer underwriting transactions and often demand higher returns to compensate for uncertainty. Improved digital property infrastructure can gradually reduce that information cost, while artificial intelligence can make those databases considerably easier to analyse.

This could influence competition between African cities. Johannesburg already benefits from comparatively sophisticated property information. Nairobi’s digital land initiatives could strengthen Kenya’s investment infrastructure if implementation continues successfully. Lagos has enormous potential because of the scale of its market, but the quality and consistency of underlying information remain critical. Cairo’s extensive development activity creates opportunities for increasingly sophisticated development and building analytics. Other African markets will face the same decision. Governments and property industries can concentrate on adopting visible AI applications, or they can invest in the less glamorous foundations required to make those systems useful: digital land registries, accurate addressing, transparent transactions, building records, planning databases and reliable market statistics.

The second approach could ultimately prove more valuable. Artificial intelligence is particularly effective when it can identify patterns across enormous amounts of information. African property markets that remain dependent on fragmented spreadsheets, paper records and privately held transaction evidence will inevitably restrict what these systems can achieve. This creates an important investment implication because better property data does more than improve technology. It can reduce uncertainty. When investors can evaluate markets more confidently, transaction costs can fall and comparisons between assets become easier. Greater transparency can also make it easier for lenders, insurers and institutional investors to price risk.

The African cities that build this infrastructure most successfully may therefore gain an advantage that extends far beyond their domestic property industries. They could become easier destinations for international capital to understand. AI will not remove Africa’s property risks, nor will it compensate for unclear ownership, inadequate infrastructure or weak market information. It can, however, dramatically increase the value of reliable data once that information exists.

That may prove to be the real transformation taking place in African real estate. The race is not simply about which developer launches an AI chatbot or which property portal introduces an automated search function. It is about which markets create the digital foundations capable of turning millions of individual property records into useful investment intelligence. For Africa’s commercial real estate industry, the cities that win that data race could eventually become the markets where investors can make decisions faster, price risk more accurately and deploy capital with greater confidence.

Source: © CIJ.World Africa Research & Analysis Team

Czech Minimum Wage Fails to Keep Pace with Rental Housing Costs

The Czech Republic’s minimum wage remained insufficient to cover basic living expenses and rental housing costs in 2025, highlighting a continuing affordability gap even as earnings at the bottom of the labour market increased. Research by the Research Institute for Labour and Social Affairs (RILSA) found that a worker receiving the minimum wage would have needed approximately 7% to 24% more net income to meet the benchmark cost of essential expenses and rental housing in full, depending on the size of the municipality. This represented a monthly shortfall of roughly CZK 1,250 to CZK 4,280.

The gross minimum wage stood at CZK 20,800 per month in 2025, corresponding to approximately 42.2% of the average gross wage. After tax and deductions, the monthly amount was around CZK 17,837. Although its purchasing power improved compared with the previous assessment, RILSA concluded that the lowest statutory wage remained insufficient under several measures, particularly once housing expenditure was included.

The findings are significant for the Czech residential market because they demonstrate that the affordability problem extends beyond the cost of buying a home. For workers at the bottom of the income distribution, conventional rental housing can itself require a level of expenditure that is difficult to reconcile with other essential household costs.

There has nevertheless been measurable improvement. RILSA’s assessment indicates that minimum earnings have strengthened relative to several benchmarks, while the gap between the statutory minimum and average earnings has narrowed. The researchers caution, however, that the improvement should not be interpreted entirely as evidence of better housing affordability or living standards, as changes to the subsistence benchmark and the treatment of normative housing costs also influenced the comparison.

The minimum wage increased again to CZK 22,400 per month at the beginning of 2026, representing 43.4% of the forecast average wage. The Czech system now uses an automatic mechanism linking future increases to expected average earnings, with the ratio scheduled to move progressively towards 47% by 2029.

A further increase is expected for 2027, when the minimum wage is set to rise to approximately CZK 24,900 per month, equivalent to around 44.6% of the average wage. The gradual increases are intended to make the development of minimum earnings more predictable while reducing the gap between workers receiving the statutory minimum and the broader labour market.

RILSA’s assessment also shows that the net minimum wage reached 46.1% of the net average wage in 2025, its highest proportion recorded so far. Since 2016, minimum earnings have generally risen faster than average and median wages, with 2021 being an exception. Minimum-wage growth also exceeded inflation in 2025.

The wider labour-market implications are important for employers as well as employees. The Czech Republic continues to have a relatively high proportion of low-paid workers compared with the OECD average, with women particularly represented in this part of the labour market. Further increases will therefore have consequences for labour costs in industries that depend heavily on lower-paid employment.

For the property sector, however, the central issue is the relationship between earnings and housing expenditure. Higher wages can improve affordability, but their effect will remain limited if rents and other household costs rise at a similar or faster rate. This is particularly relevant for lower-income households dependent on the rental sector and for locations where competition for available homes remains strong.

The latest findings consequently expose two connected parts of the Czech affordability challenge. Wage policy can progressively increase the resources available to lower-paid households, but it cannot independently reduce the cost or increase the availability of rental housing. Closing the remaining affordability gap will depend not only on future earnings growth, but also on how much housing is delivered, where it is built and what proportion remains financially accessible to workers on lower incomes.

Source: CTK

Croatia’s Hotels May Find Their Next Growth Phase Without Adding More Tourists

Croatia’s hotel market is approaching a different kind of growth challenge. After years in which expanding visitor numbers helped underpin the country’s tourism economy, the next investment cycle may depend increasingly on generating more income from existing demand rather than relying on another record season. The first signs of that challenge appeared clearly in June 2026, when Croatia recorded approximately three million arrivals in commercial accommodation and 13.5 million overnight stays. Arrivals decreased 6.6 percent from a year earlier and nights fell 6.1 percent, while overnight stays by international visitors declined 7.5 percent.

Those figures do not indicate that Croatian tourism has entered a broad downturn. Across the first six months of 2026, total arrivals and overnight stays were still approximately 0.5 percent higher than during the same period of 2025. June should therefore be regarded as a weak month within an otherwise relatively stable first half rather than evidence of a sustained decline. What happened inside the hotel sector is more significant for property investors. Hotel overnight stays fell by only 1.7 percent during June, considerably less than the contraction across commercial accommodation as a whole, while hotel room occupancy remained virtually unchanged at 72.1 percent compared with 72.0 percent a year earlier.

That resilience raises a different question about the future of Croatian hospitality. If hotels can maintain utilisation even when overall visitor numbers weaken, future investment performance may depend less on increasing the number of guests and more on increasing the economic contribution of each stay. Room pricing is one part of the equation, but restaurants, bars, wellness facilities, conferences, events, excursions and other services can all influence how much income a property generates from each visitor. A hotel that persuades guests to spend more within the property can potentially increase revenue without requiring significantly more occupied rooms.

Lengthening the operating season could be equally important. Croatia remains highly dependent on summer tourism, and hotels that generate most of their income during a relatively short peak period carry considerable seasonal exposure. Properties capable of attracting guests during spring and autumn can spread operating costs across more months while reducing their dependence on exceptional July and August performance.

This could influence how investors approach the country’s existing hotel stock. In established Adriatic destinations, the most attractive opportunity may sometimes be an existing property in an exceptional location rather than a new development. Prime waterfront sites, historic urban locations and established resort grounds are inherently limited. Acquiring and improving an existing hotel can therefore provide an alternative route to growth. Investment can modernise rooms, restaurants, wellness areas, pools, conference facilities and outdoor spaces while improving energy efficiency and operational performance. The objective would not necessarily be to create additional beds, but to make every existing room more productive.

Dubrovnik provides perhaps the clearest example of this approach. The city’s international profile allows well-positioned hotels to compete for affluent visitors, while its historic environment and physical constraints limit how far tourism volumes can expand without creating additional pressure on the destination. For investors in Dubrovnik, increasing the value generated by each visitor may therefore make more sense than pursuing continuous increases in guest numbers. Higher-quality accommodation, stronger food and beverage concepts, wellness and demand outside the peak season could all form part of that strategy.

Split faces a different set of conditions. It combines conventional city demand with leisure tourism and its role as an important gateway to the Croatian islands. Hotels also compete with a substantial private accommodation sector. That competition can encourage professional hotel operators to differentiate themselves through facilities and service rather than price alone. Business events, organised groups, restaurants and wellness facilities can also help hotels develop sources of demand that are less dependent on the peak summer holiday period.

Istria already demonstrates how a destination can broaden its tourism proposition beyond beaches. Food, wine, cycling, wellness and proximity to Central European markets provide reasons for visitors to travel outside the hottest months of the year. For property owners, that creates opportunities to reposition hotels around experiences that support longer operating seasons. A resort capable of attracting guests in April, May, September and October has fundamentally different economics from one heavily dependent on a few summer weeks.

Kvarner offers another potential repositioning market. Its established resort towns, accessibility from Central Europe and history of health and wellness tourism provide a foundation for investment in existing accommodation. Some older properties may therefore become more interesting as redevelopment opportunities than as hotels operating in their current form. Modernisation could potentially move assets into higher-value segments without materially increasing accommodation capacity in the destination.

The islands present a different investment equation. Limited supply, distinctive landscapes and waterfront locations can support premium hospitality. Resorts capable of combining accommodation with restaurants, wellness, private experiences and other services may be able to generate substantially more spending per visitor. But islands also introduce additional costs. Labour can be harder to secure, supplies may be more expensive to transport and infrastructure can be more constrained. Seasonal operations can further increase the complexity of running large properties. For this reason, higher room prices should not automatically be interpreted as higher profitability.

That distinction applies throughout Croatia. A hotel can increase revenue while simultaneously facing higher wages, energy bills, food costs, maintenance expenses and financing charges. Investors therefore need to understand how much additional income translates into operating profit rather than concentrating exclusively on occupancy or advertised room rates. Management quality consequently becomes increasingly important. Two hotels in similar locations can produce very different results depending on pricing strategy, staffing, distribution costs, restaurant performance and the ability to encourage additional guest spending.

International operators and brands could play a greater role in some parts of this market. Their reservation systems, loyalty programmes and global distribution can help properties reach higher-spending international customers. But branding is not automatically the correct strategy for every hotel. Strong independent properties can also succeed by offering a distinctive local experience. The investment decision ultimately depends on which operating model creates the greatest sustainable value for the individual asset.

New hotels will still be required in locations where suitable modern accommodation is insufficient or where exceptional development sites become available. But Croatia does not necessarily need another hospitality cycle defined primarily by adding rooms. A substantial part of future investment could instead be directed towards transforming what already exists.

That would have implications beyond individual properties. Improving the quality and productivity of existing hotels could increase tourism income without requiring equivalent growth in visitor numbers, particularly in destinations already experiencing pressure during the summer peak. It could also encourage greater attention to year-round tourism. Wellness, gastronomy, cultural travel, sporting events, conferences and other activities can help destinations attract guests outside traditional holiday periods.

The June figures make this discussion particularly timely. Croatia experienced a noticeable decline in overall tourism activity compared with June 2025, yet hotel occupancy remained almost unchanged and hotel overnight stays declined considerably less than the broader market. Meanwhile, the first half of 2026 remained slightly ahead of the previous year overall. That combination does not prove that Croatia has successfully shifted towards higher-value tourism, nor does it establish that hotel profitability is increasing. What it does show is that expanding visitor numbers cannot be the only measure used to judge the health of the country’s hospitality property market.

For investors considering Dubrovnik, Split, Istria, Kvarner or the islands, future performance will increasingly depend on the quality of the asset, its operating season, its ability to command appropriate pricing and how much additional spending it can capture from guests. Croatia has already built one of Europe’s most successful tourism destinations around the strength of its coastline, cities and islands. Its next hotel investment opportunity may come from extracting greater economic value from those advantages rather than continually increasing the number of people using them.

The next phase of Croatian hospitality could therefore be defined not by how many additional beds are built, but by how much more effectively the country’s existing hotel rooms are used.

Source: CIJ.World Research & Analysis Team

AI Is Extending the Economic Life of the World’s Factories

Artificial intelligence is beginning to change how manufacturers think about one of their largest capital commitments: the machinery already installed inside their factories. Rather than replacing ageing production equipment with entirely new automated plants, manufacturers are increasingly using sensors, machine data and AI-assisted monitoring to understand when equipment is deteriorating and intervene before a failure interrupts production. The potential financial impact can be substantial. Unplanned equipment failure can stop an entire production line, disrupt deliveries, increase labour costs and create problems elsewhere in the supply chain.

At AI4 2026 in Las Vegas, manufacturing executives from Kimberly-Clark, BlueScope and commercial food-equipment producer Henny Penny discussed how predictive maintenance is moving from isolated technology experiments towards a broader strategy for managing industrial assets. The discussion, moderated by Woven Capital, Toyota’s growth-stage investment arm, highlighted an important shift in industrial AI. Predictive maintenance itself is not new. Manufacturers have monitored vibration, temperature, electrical current and other machine characteristics for decades. What has changed is the ability to collect information more cheaply, combine it with historical maintenance records and use machine-learning systems to identify patterns that employees may not recognise until equipment is much closer to failure.

Traditional industrial maintenance generally follows three approaches. Equipment can be repaired after it fails, serviced according to a predetermined schedule whether it requires intervention or not, or monitored continuously so maintenance can be performed when the data indicates that deterioration is developing. The third approach has become considerably more practical as sensors have become cheaper and AI has improved the ability to interpret large quantities of operational information. For manufacturers, the objective is not necessarily to eliminate equipment failure. It is to convert unexpected downtime into planned downtime. Knowing several weeks in advance that a bearing, motor, pump or other critical component is deteriorating gives plant managers the opportunity to schedule repairs, secure spare parts and reorganise production rather than dealing with an emergency shutdown.

Kimberly-Clark described how vibration and electrical-current monitoring is already being used across parts of its industrial asset base. Equipment including bearings, valves and rotating machinery generates signatures that can indicate changes in operating condition. In chemical processes, similar monitoring can identify problems such as leaking valves or changes that could affect the production process. One particularly expensive problem is an unexpected break during continuous manufacturing. According to the company’s presentation, an emergency interruption on some production lines can carry costs reaching approximately $250,000 per hour. Predictive monitoring can potentially identify deteriorating conditions weeks beforehand, allowing the company to move maintenance into a controlled production window.

That distinction is economically important. A machine may still require exactly the same repair, but the financial consequences can be dramatically different depending on when the work takes place. Planned maintenance allows managers to adjust production schedules, prepare replacement components and coordinate employees before the line is stopped. An unexpected breakdown can simultaneously create lost production, overtime, emergency repair costs and missed customer commitments.

The panel also challenged the assumption that manufacturers need to replace old equipment before they can benefit from AI. Industrial facilities frequently contain machinery that has operated successfully for decades. In capital-intensive sectors such as steel, replacing functioning equipment simply because it lacks modern digital controls can be difficult to justify. BlueScope described machinery that may have been installed 20 or 30 years ago but remains capable of safely producing the required product. Historically, connecting such assets to modern monitoring infrastructure could require substantial investment in controllers, wiring and plant systems. In some cases, the cost of digitally upgrading an individual motor or component could reach well into six figures, effectively preventing the investment.

Wireless monitoring and lower-cost sensing technologies are changing those economics. Instead of rebuilding the underlying machine, manufacturers can increasingly add external monitoring equipment and connect operational information to newer analytical platforms. That can allow a decades-old asset to participate in a modern predictive-maintenance programme without requiring a complete equipment replacement. For industrial property owners and manufacturing companies, this creates an important capital-allocation question. Older machinery is not necessarily obsolete simply because it predates connected manufacturing. If equipment remains safe, reliable and capable of producing the required quality, digital monitoring may extend its useful economic life considerably.

The same logic can apply to entire industrial facilities. The future of manufacturing may therefore involve fewer completely automated greenfield factories than some technology forecasts suggest. A substantial portion of industrial AI investment could instead flow into retrofitting and digitally enhancing existing plants. However, the panel repeatedly warned against adding sensors simply because the technology is available. Collecting additional information creates cost, complexity and cybersecurity exposure. Every connected industrial device represents another potential access point into operational technology infrastructure, while the resulting data still needs to be stored, analysed and converted into action.

A factory does not necessarily benefit from receiving dozens of different signals from a machine when one reliable indicator would provide enough information to make the maintenance decision. The value comes from identifying which measurement matters and what employees should do when it changes. Kimberly-Clark illustrated the issue through its large manufacturing operation at Beech Island, South Carolina, where parts of the industrial infrastructure are many decades old. Some equipment continues to contain analogue components because converting every element to digital technology would create substantial cost and potentially require production downtime that cannot be economically justified.

This is where the economics of industrial AI become more complicated than simply comparing the price of sensors with the cost of a machine. Manufacturers need to consider the total cost of ownership created by additional connected equipment, software licences, cybersecurity, data infrastructure and long-term maintenance. The panel provided an example of a predictive-maintenance project that successfully detected a pump problem but still failed economically. The technology could identify the condition, but doing so required sufficiently sophisticated equipment that the monitoring system cost too much relative to the value of the pump and the consequences of its failure. The technically successful project was therefore discontinued.

That example captures one of the most important lessons from the discussion. Not every failure needs to be predicted. Sometimes the most rational maintenance strategy is to keep a replacement component nearby and allow the existing one to run until it fails. The decision depends on criticality. A relatively inexpensive component with redundancy and little effect on production may not justify continuous monitoring. A single component capable of shutting down an entire production process can justify considerably greater investment.

Henny Penny illustrated this through commercial restaurant equipment. A restaurant fryer can contain multiple heating elements, meaning failure of one may still allow the kitchen to continue operating. A critical pump, however, may have no equivalent redundancy. If that component fails, the restaurant can lose its ability to produce an important part of its menu. Predictive maintenance therefore needs to begin with the economic consequence of failure rather than with the technology capable of detecting it. Manufacturers need to understand what happens when the asset stops, how quickly it can be repaired, whether another machine can take over and how much the disruption costs.

The required warning period also varies significantly. Technology companies frequently market predictive systems around their ability to identify failures weeks in advance, but such long forecasts may provide little additional value. Henny Penny found that equipment problems in restaurants can already take several days to progress from initial failure to technician arrival because employees first need to report the problem and service teams then need to dispatch someone. For certain critical equipment, knowing four or five days before failure may therefore provide sufficient time to intervene. This illustrates why predictive maintenance cannot be standardised purely around technical performance. A model predicting a failure 30 days ahead is not automatically more valuable than one providing five days of warning. The relevant measure is whether the prediction gives the organisation enough time to take the economically appropriate action.

The return on investment can also appear in areas beyond conventional calculations of production uptime. Henny Penny reported feedback from a major restaurant customer that equipment failures increase employee stress because workers must suddenly adapt service around unavailable machinery. Avoiding unexpected breakdowns can therefore improve working conditions as well as operational performance. For large manufacturers, the consequences can extend through inventory and retail distribution. Kimberly-Clark explained that production interruptions can affect commitments to major retailers and alter the timing of product flows through warehouses and stores. A failure at the factory can consequently create costs well beyond the machine where the problem originated.

Environmental performance provides another potentially significant benefit. In chemical-intensive manufacturing, deteriorating equipment can increase the consumption or leakage of process materials before the problem becomes severe enough to stop production. Monitoring those changes can identify inefficiency earlier and potentially reduce waste, energy consumption and environmental exposure. Predictive maintenance therefore intersects increasingly with corporate sustainability strategies. Equipment that operates outside its optimal range can consume more electricity, water or raw materials. A deteriorating bearing, for example, can require more energy before the change becomes obvious to an operator. Detecting that deterioration earlier can produce both maintenance and energy savings.

However, the business case needs to capture these benefits explicitly. BlueScope argued that condition-monitoring programmes should be able to demonstrate financial payback. Manufacturers need systems for tracking not only the cost of deploying technology but the value of failures prevented, production preserved and other operational improvements. Demonstrating successful returns also helps organisations expand programmes. Once employees and management can see that a particular monitoring application has paid for itself, gaining support for deployment on additional assets becomes easier.

Scaling remains one of the industry’s largest difficulties. A predictive-maintenance model that works in one factory cannot necessarily be copied directly into another. Kimberly-Clark operates a large global manufacturing network in which plants contain equipment from different generations and vendors, integrated through different systems and maintained by employees with different operating histories. The panel summarised the problem by noting that manufacturing patterns may repeat while the underlying implementation rarely does. Similar machines can experience comparable failure modes, but the code, integrations and operational environment are seldom identical.

This complicates the economics of scaling industrial AI. A company may successfully demonstrate a predictive model on one production line only to discover that deploying it across dozens of plants requires substantial additional integration and calibration. Industrial AI therefore differs from many corporate software applications where one system can be rolled out relatively uniformly across an organisation. Individual machines can also develop their own operating signatures. Henny Penny described establishing baseline characteristics when equipment leaves the production line. Once that machine is operating at a customer location, its subsequent behaviour can be compared with its own original condition as well as with broader fleet data.

At sufficient scale, this creates potentially valuable information. A manufacturer with tens of thousands of connected machines in customer locations can identify patterns across the installed base while still recognising differences between individual units. But the risks of model errors also increase dramatically. A false maintenance alert affecting one machine is inconvenient; the same error replicated across tens of thousands of connected units can create widespread operational disruption.

Human operators therefore remain central to predictive maintenance. Experienced maintenance employees often know individual machines intimately and can recognise changes through sound, vibration or behaviour. AI needs to earn their trust rather than simply override their judgement. False alarms are particularly damaging. If a monitoring system repeatedly warns about failures that never occur, operators can quickly stop paying attention. Once that happens, even a correct warning may be ignored.

Successful implementation therefore requires collaboration between data specialists, reliability engineers, maintenance teams and machine operators. AI can identify abnormal patterns and recommend action, but employees need to understand what the warning means and what should happen next. Visualisation and notification are also critical. A sophisticated predictive model creates little value if its warning is buried inside a dashboard that nobody checks. Information needs to reach the right employee at the moment when action is still possible.

This reinforces the idea that predictive maintenance is ultimately an operational system rather than simply an AI model. Sensors, data infrastructure, analytics, notifications, maintenance processes, spare-parts availability and human decision-making all need to work together. The same complexity affects decisions over whether manufacturers should build AI capabilities internally, purchase commercial platforms or work with external partners.

The panel suggested that commodity capabilities are often better purchased. Common equipment signatures, such as bearing vibration, are not necessarily sources of competitive advantage and may already be addressed effectively by specialised vendors. Manufacturing processes that are unique to a company’s products or intellectual property can justify custom development. Kimberly-Clark pointed to manufacturing characteristics involving absorbency, chemical balances and specialised production techniques as examples where internal knowledge becomes strategically important.

The emerging model is therefore likely to combine buying, building and partnering. Manufacturers can purchase standard monitoring technologies while developing proprietary models around processes that differentiate their products. AI itself is also making internal development easier. BlueScope noted that modern AI tools allow operational and engineering teams to perform analytical and development work that previously required external consultants. This could reduce the cost of creating specialised applications and make smaller industrial AI projects economically viable.

The more important opportunity may ultimately come from combining information that already exists across the factory. Sensor readings represent only one part of the picture. Maintenance-management systems contain years of work orders, repair histories and technician comments that have historically been difficult to analyse at scale. Bringing those records together with real-time machine data can give managers a much richer understanding of asset condition. This suggests that some of the most valuable industrial AI applications may not require additional sensors at all. Existing error codes, maintenance records, production data and service histories can already contain enough information to identify useful patterns.

Manufacturers also need to consider ownership of this information when selecting technology vendors. Industrial operating data can reveal production volumes, equipment performance, proprietary processes and weaknesses within a manufacturing system. Moving that information entirely into a vendor-controlled platform can create long-term dependence. The panel warned that companies need to understand where their production data resides, who controls it and how easily it can be moved. A manufacturer that places its operational history inside a proprietary external platform can eventually find itself effectively paying ongoing rent to access information generated by its own equipment.

The issue is becoming more significant as technology vendors add AI capabilities and increase software costs. Manufacturers therefore need to consider the long-term total cost of ownership rather than simply the initial subscription price. For industrial companies and investors, the larger implication is that AI may change the economics of existing manufacturing assets before it transforms factories into fully autonomous facilities. The ability to monitor older machinery cheaply, extract information from maintenance histories and schedule interventions before failure can extend asset life and improve the productivity of capital already invested.

That could influence future industrial CAPEX strategies. Companies may find that retrofitting selected high-value assets produces better returns than replacing entire production lines. Older factories with strong physical infrastructure could remain economically competitive for longer if digital monitoring compensates for some of their technological limitations. The investment case for industrial modernisation therefore becomes more selective. Rather than spending capital uniformly across a plant, manufacturers can identify the machines whose failure carries the greatest economic consequences and concentrate technology investment there.

Predictive maintenance is consequently becoming as much a capital-allocation discipline as a technology programme. The most sophisticated model does not automatically produce the best result, and the most connected factory is not necessarily the most efficient. The real advantage comes from understanding which assets matter, which failures need to be predicted, how much warning is actually required and what action employees should take when the warning arrives.

AI is making those decisions easier by allowing manufacturers to extract more value from data that machines have been producing for years. But the factories likely to benefit most will not necessarily be those installing the greatest number of sensors or deploying the most AI. They will be the ones that use the technology selectively to keep critical equipment running, reduce unplanned downtime and extract more productive life from billions of dollars already invested in industrial assets.

Source: CIJ.World Research & Analysis Team

Dutch Healthcare Property Is Growing Faster Than Its Investment Market

Healthcare real estate is becoming one of the most closely watched parts of the Dutch property market. An ageing population is creating a long-term requirement for senior housing and care facilities, government funding is being directed towards increasing supply, and investors are searching for property capable of delivering dependable income over extended periods. The first half of 2026 appears at first glance to confirm that healthcare has already become a major investment sector. Around €847 million of activity was recorded by one leading market measure. Look beneath that figure, however, and the market is considerably more complicated.

Another assessment of Dutch healthcare transactions records approximately €550 million across 27 deals during the same six months. The difference largely reflects the treatment of the Dutch healthcare portfolio involved in the combination of Aedifica and Cofinimmo. Including the portfolio produces a much larger investment total. Excluding the corporate combination from conventional property turnover provides a figure closer to the amount of healthcare real estate bought and sold through ordinary investment transactions. Neither approach makes the underlying healthcare story disappear. The approximately €550 million of conventional activity was still substantially higher than the roughly €272 million recorded during the first half of 2025. The market therefore expanded strongly even without relying on the exceptional corporate event. The difference between the two 2026 totals instead reveals something important about the maturity of the sector: Dutch healthcare property remains small enough for a single large transaction to transform the headline numbers.

The €210.5 million Nightingale portfolio transaction demonstrates both the opportunity and the concentration. A deal of that size provides clear evidence that substantial capital can be deployed into Dutch healthcare property when an appropriate portfolio becomes available. At the same time, one transaction accounted for a significant proportion of conventional first-half investment. That is very different from a deep market in which numerous large assets and portfolios trade regularly. The long-term case for expanding the sector is nevertheless powerful. The Netherlands estimates that approximately 290,000 additional homes suitable for older residents will be needed by the end of 2030. Plans exist for a substantial proportion of that requirement, but tens of thousands of additional projects are still needed, particularly in forms of housing that combine independent living with communal facilities or the ability to provide increasing levels of care.

That requirement creates an investment market much broader than traditional nursing homes. Senior apartments, clustered housing, assisted living, nursing facilities, clinics, medical centres and rehabilitation properties can all form part of the healthcare real estate universe. They may respond to the same demographic trend, but they do not represent the same investment. Senior housing can behave much like residential property. Demand depends on location, affordability, accessibility and the number of older households seeking suitable accommodation. Residents can live largely independently while obtaining healthcare separately when required. At the other end of the spectrum, a specialised nursing facility may depend almost entirely on a professional care provider capable of operating the building and supporting residents with complex needs.

For investors, this distinction makes the organisation occupying or operating the property unusually important. A long lease can provide visibility over future rental income, but the value of that lease ultimately depends on whether the tenant can afford its obligations. Healthcare operators have to manage wages, energy, regulation and increasingly complex care requirements while remaining within the financial structure of the Dutch healthcare system. Rent therefore cannot be analysed separately from the economics of care. Contractual indexation may protect investors against inflation, but continued increases in property costs become difficult if an operator’s revenues do not rise sufficiently to absorb them. A lease that looks attractive on paper can become less secure if the business responsible for paying the rent is under sustained financial pressure.

The labour market adds another layer of risk. The Netherlands expects significant shortages of healthcare workers during the coming decade, with elderly care particularly exposed. This creates a paradox for healthcare property. The ageing population increases demand for facilities while simultaneously increasing the number of employees required to operate them. A modern nursing home in an area with rapidly increasing numbers of elderly residents may therefore appear to have exceptionally strong demand. But if its operator cannot recruit enough nurses and carers, demographic demand alone cannot guarantee successful operation. For investors, access to labour could become increasingly relevant when assessing locations. That means looking beyond the traditional healthcare catchment area. Public transport, commuting times and the availability and cost of housing for employees can influence whether a facility is practical to operate. A location that works for residents but not for staff may ultimately create difficulties for the tenant and therefore for the property owner.

Development presents another challenge. The Netherlands does not simply need more ordinary apartments occupied by older people. A substantial part of the requirement involves homes designed so residents can continue living independently as their mobility declines or their need for care increases. Such properties can require step-free layouts, wider doors and corridors, larger bathrooms, lifts and additional space allowing healthcare workers to assist residents. Communal facilities may also be required to reduce isolation and support services within the development. These features can increase construction costs while using space that would otherwise generate rent. Government support reflects the difficulty of delivering these properties. Funding made available during 2026 is intended to encourage the development of care-ready homes and shared facilities, while additional money has been committed for the coming years to accelerate senior housing. Public intervention is therefore helping to create a development pipeline, but private capital will still need projects where land costs, construction expenditure and achievable income produce acceptable returns.

The opportunity is not limited to new construction. Existing offices, hotels and other buildings could potentially be adapted for senior housing or healthcare uses. In a country simultaneously dealing with housing shortages and obsolete commercial property, conversion can appear attractive. The physical reality is more complicated. Buildings designed for offices or hotels do not automatically work for people with reduced mobility or for healthcare operators. Floor layouts, lifts, fire safety, daylight, bathrooms, circulation space and access for staff can determine whether conversion is financially realistic. Some buildings will adapt successfully. Others may require so much reconstruction that demolition and redevelopment become more economical. Healthcare property therefore cannot simply become an automatic destination for unwanted commercial property. The building must work for the people receiving care and for those providing it.

Location requirements also differ across the sector. Independent senior housing benefits from proximity to shops, public transport, doctors and social facilities. Nursing homes require sufficient staff within reach. Medical centres need accessible locations serving substantial populations. Rehabilitation facilities may require specialised accommodation and different transport arrangements. These differences make healthcare property more operationally complex than its reputation for long leases and defensive demographic demand sometimes suggests. They also explain why transparency matters. The Dutch healthcare transaction market does not yet provide the same depth of information available in some established property sectors. Limited disclosure of rental details across transactions makes it harder to compare assets and determine precisely how investors are pricing tenant strength, lease conditions and building quality.

Headline yields alone cannot solve that problem. A property producing a higher return may have a weaker operator, greater future capital requirements or limited possibilities for alternative use. Another asset producing a lower return may occupy a superior location, have a stronger tenant and remain adaptable if healthcare delivery changes. Investors therefore need to understand both the real estate and the care business behind it. This could encourage further specialisation within the investment market. Residential investors can target senior apartments and independent living. Dedicated healthcare funds can concentrate on nursing and assisted-living properties. Institutional investors seeking long-duration income can acquire modern facilities occupied by financially strong organisations. Investors prepared to take development risk can pursue conversions and new projects. Over time, this could turn Dutch healthcare property into several related institutional markets rather than one asset class.

One of the most interesting models may be developments capable of supporting residents through different stages of later life. Independent apartments, communal facilities and access to care can be combined so that residents do not necessarily need to leave their neighbourhood when their circumstances change. As their needs increase, additional services can be provided around them. This has implications for the wider housing market. Building attractive homes for older residents can encourage households to move from properties that no longer suit their needs. Larger existing homes can then become available to younger households and families. Senior housing can therefore contribute to housing-market movement rather than simply adding another specialist category of accommodation. For investors, this strengthens the connection between healthcare and residential property. Some of the largest opportunities created by ageing may ultimately involve housing where care can be introduced when required rather than traditional institutional facilities.

The first-half 2026 investment figures should be understood within this much larger structural change. The €847 million headline demonstrates the scale the market can appear to reach when a major corporate portfolio event is included. The approximately €550 million spread across 27 conventional transactions gives a clearer indication of the underlying investment market. That underlying figure is arguably the more significant one. It more than doubled from the comparable period of 2025, demonstrating that investor activity strengthened even without the exceptional transaction. But it also shows how far the sector still has to develop. A mature institutional property market requires regular supply, multiple large buyers and sellers, transparent rental evidence and sufficient transaction volume that individual deals do not radically alter annual statistics. Dutch healthcare property is progressing towards that position, but it has not necessarily reached it yet.

Demographics provide a strong foundation. The Netherlands will need substantially more senior housing and care-related property. Government funding is supporting development, while institutional and specialist investors are demonstrating an appetite for the sector. The difficult part is turning that demand into investible buildings. Healthcare operators must remain financially sustainable. Facilities need enough employees. Development costs must be supported by achievable rents. Buildings need to remain suitable as care requirements change. Investors need reliable information about leases and transactions, while enough assets must reach the market to allow capital to build diversified portfolios.

Those challenges do not weaken the healthcare property story. They define it. The Netherlands is developing a larger healthcare real estate market because the demographic requirement is becoming impossible to ignore. The approximately €550 million invested through 27 transactions during the first half of 2026 suggests that this development is already translating into genuine investment activity. The larger headline number makes the sector look bigger. The underlying transactions make the investment story more convincing.

Source: CIJ.World Research & Analysis Team

AI Is Accelerating Drug Discovery, but Clinical Development Is Becoming the New Bottleneck

Artificial intelligence is dramatically increasing the speed at which pharmaceutical companies can identify potential drug candidates, analyse biological information and automate research tasks. But as the earliest stages of drug development become faster, another problem is becoming increasingly visible: the rest of the pharmaceutical development system cannot necessarily move at the same speed. That emerging imbalance was one of the central themes of a life-sciences panel at AI4 2026 in Las Vegas, where representatives from pharmaceutical companies, clinical research, biotechnology and AI infrastructure discussed how artificial intelligence is changing the journey from laboratory research to medicines reaching patients.

The panel was moderated by Bryson Tombidge, CEO of Tono Health, and included Talia Fakhoury, Chief AI and Regulatory Strategy Officer at Parexel and a former US Food and Drug Administration official; Laura Boykin-Okalebo, a computational biologist working with AI infrastructure provider Nebius; Patrick Lerch, Senior Vice President of Clinical Data Sciences at Gilead Sciences; and an AbbVie executive responsible for clinical systems, digital operations and AI implementation in clinical development. The discussion suggested that AI’s biggest contribution may ultimately come not simply from discovering more molecules, but from reducing the time and resources required to move promising treatments through clinical development.

The starting point was a striking change taking place in pharmaceutical research. AI can increasingly analyse biological targets, screen potential compounds, model proteins and optimise candidate molecules considerably faster than traditional laboratory processes alone. Research teams can therefore produce larger numbers of potential drug candidates in shorter periods. That represents an important scientific advance, but it also risks transferring pressure further along the pharmaceutical development chain. A molecule that appears promising still needs to progress through preclinical testing and several stages of human clinical trials before regulators can consider approving it. Those processes remain expensive and time-consuming, and some elements cannot simply be accelerated through additional computing power. Human biology operates according to its own timetable, while regulators continue to require evidence demonstrating that medicines are safe and effective.

Lerch described the resulting flow of potential compounds emerging from research as a growing wave heading towards clinical development. For pharmaceutical companies, this creates a resource allocation problem. AI may generate more scientifically plausible opportunities, but companies still have finite budgets, clinical-development teams, trial sites and eligible patients. Every decision to advance another molecule therefore remains an investment decision. This means the industry’s next challenge is increasingly about improving the efficiency of clinical development itself.

AbbVie is examining the critical path between the start of clinical development and the eventual submission of a medicine for regulatory approval, looking for individual stages where AI can remove delays. Potential applications include preparing clinical systems faster, accelerating analysis after trials are completed and assisting with preparation of clinical study reports and regulatory documentation. The objective is not necessarily to eliminate large numbers of jobs or simply reduce operating expenses. The more strategically important measurement is time. Removing several weeks from multiple stages of development can eventually shorten a programme by months. Across a large pharmaceutical portfolio, those savings can become commercially significant while potentially allowing successful treatments to reach patients earlier.

Gilead is approaching the opportunity through both scientific and operational applications. On the scientific side, AI is being explored in medical imaging to analyse tumour burden and help researchers evaluate how cancer treatments are performing. Faster analysis could allow development teams to make earlier decisions about whether a programme should progress to another clinical phase. On the operational side, one of the more immediate opportunities involves software development and statistical programming. Pharmaceutical companies produce substantial quantities of specialised code to prepare, transform and analyse clinical data. Much of this work is created for individual studies or analyses. AI-assisted coding can accelerate these processes while retaining validation and human oversight, allowing information to move through the clinical-development system more quickly.

The distinction between speed and useful progress emerged repeatedly during the discussion. AI can produce an answer or complete a task considerably faster, but speed alone does not guarantee that the organisation is moving in the correct direction. Pharmaceutical companies operate in a highly regulated environment where inaccurate analysis can ultimately affect regulatory submissions and patient safety. Human oversight therefore remains particularly important. AI-generated work that feeds into regulatory documentation cannot simply be accepted because it was produced quickly. Companies need quality controls capable of checking outputs while ensuring that automation does not introduce errors or unsupported conclusions into clinical-development processes.

This is creating a different challenge from the one facing many other industries adopting generative AI. Pharmaceutical companies need to balance automation against scientific evidence, regulatory requirements and patient risk. An AI system capable of reducing a four-week analytical task to a day may create enormous value, but only if the resulting work meets the same or higher quality standards. Clinical research organisations are already reporting measurable improvements in some administrative processes. Fakhoury said Parexel has been using AI to reduce the time required to prepare regulatory documentation and regulatory-grade datasets. The broader significance is that these relatively routine processes sit between important milestones in drug development. Accelerating enough of them could collectively reduce the time between clinical phases.

The more ambitious opportunity involves changing the structure of clinical trials themselves. One area receiving increasing attention is the use of computational models to estimate how patients might have responded without receiving an experimental treatment. In carefully designed circumstances, these approaches could supplement information from traditional control groups and potentially reduce the number of patients required to receive a placebo. This could be particularly valuable for rare diseases, where finding sufficient numbers of eligible patients is difficult and allocating some participants to placebo groups can make recruitment even harder. AI combined with historical clinical information and statistical modelling may eventually allow researchers to extract more information from smaller patient populations.

However, the term “digital twin” is increasingly being used to describe several different technologies. The panel cautioned against treating it as a single concept. In some applications, it refers to statistical models used to estimate a patient’s likely response in a control group. Elsewhere, it can refer to synthetic or external control groups built from historical health records, while other organisations use the term for virtual representations of biological systems or operational processes. The underlying opportunity is nevertheless significant. Better modelling could help pharmaceutical companies estimate treatment effects more accurately, determine appropriate trial sizes and potentially reduce uncertainty before expensive late-stage studies begin.

AI can also address another persistent clinical-trial problem: finding patients. Matching patients to studies currently requires analysing complex eligibility criteria against fragmented healthcare information. AI can potentially search electronic health records more efficiently and identify patients whose medical profiles make them suitable for particular trials. Yet this immediately exposes one of the industry’s largest structural problems. Healthcare information remains fragmented across hospitals, insurers, laboratories, research organisations and different technology systems. In the United States in particular, data required for sophisticated patient matching may exist across numerous organisations that cannot easily exchange it. AI therefore does not eliminate the pharmaceutical industry’s data problem. In many cases it makes the importance of that problem more visible.

The same applies to the transition between animal research and human clinical trials. Despite advances in laboratory science, predicting how findings from animal models will translate into humans remains difficult. AI could potentially improve estimates of appropriate first-in-human doses, likely treatment effects, safety risks and other biological responses, but this remains one of the hardest problems in drug development. The panel identified this translational stage as potentially more important than simply designing molecules faster. If AI can substantially improve predictions about which treatments are most likely to work safely in humans, pharmaceutical companies could avoid committing years of development and substantial capital to programmes that eventually fail.

Until that improves, clinical development is likely to remain slower than AI-driven discovery. Researchers may become capable of generating candidate molecules at unprecedented speed, but each candidate still enters a system requiring scientific validation, clinical trials, regulatory scrutiny and real patients. This creates the possibility of a pharmaceutical pipeline bottleneck. Rather than suffering from too few promising compounds, companies could increasingly face more candidates than their clinical-development organisations can realistically process.

Compute infrastructure represents another emerging constraint. Modern biological AI models can require substantial GPU capacity, particularly when researchers are working with genomics, medical imaging, molecular simulations and increasingly sophisticated foundation models. Boykin-Okalebo said demand for advanced computing infrastructure continues to exceed available supply in parts of the market. For biotechnology start-ups without the financial resources or technology infrastructure of global pharmaceutical companies, access to suitable computing capacity can determine whether research progresses at all.

Research computing is consequently becoming part of biotechnology business planning. A start-up may have promising science and financing but still struggle if it cannot secure the computing resources required to train or operate its models. This means founders and investors increasingly need to consider compute requirements alongside laboratory space, clinical strategy, intellectual property and capital requirements. The infrastructure challenge is not simply obtaining GPUs. Healthcare and pharmaceutical workloads frequently involve sensitive patient information, creating additional requirements around storage, encryption, cybersecurity and data location. Computing capacity and data storage therefore need to be designed together.

If sensitive information must remain in a particular jurisdiction while the available computing infrastructure is located elsewhere, the theoretical performance of the AI hardware becomes less relevant. The architecture needs to satisfy privacy and regulatory requirements while allowing data to move efficiently between storage and compute. This creates an important infrastructure investment angle around the expansion of AI in life sciences. Data centres supporting pharmaceutical and healthcare workloads may need configurations specifically designed for regulated information, high-performance computing and secure connections to large datasets. As biological AI becomes more sophisticated, proximity between compute and data could become increasingly important.

Regulation itself may not be as significant an obstacle as some companies assume. Drawing on her previous experience at the FDA, Fakhoury argued that many operational uses of AI within pharmaceutical companies sit outside direct regulatory oversight. AI used to help prepare documents or improve internal processes is different from a system whose output becomes evidence supporting the safety or effectiveness of a medicine. She cautioned companies against automatically applying validation procedures created for older deterministic software systems to every modern AI application. Excessively conservative interpretations can increase costs and delay projects without necessarily improving patient protection.

The more appropriate approach is to evaluate systems according to their actual risk and intended use. AI directly influencing clinical evidence or patient safety requires far greater scrutiny than technology automating an internal administrative task. The European environment adds another layer through data-protection requirements such as GDPR, particularly when patient information is involved. As clinical research becomes increasingly international, pharmaceutical companies and their technology providers need infrastructure capable of operating across different regulatory and data-governance regimes.

This reinforces the importance of global clinical research. AI may accelerate the creation of new drug candidates, but trials still require patients. Access to diverse patient populations, healthcare systems and clinical sites could therefore become even more strategically important as the number of potential therapies entering development increases. The panel also highlighted the importance of including more geographically diverse researchers and datasets in AI development. Models trained predominantly on information from limited populations may perform differently when applied elsewhere. Expanding participation in AI-enabled medical research could improve both scientific representation and the ability to develop treatments for wider populations.

Another obstacle is organisational rather than technological. Pharmaceutical companies cannot simply provide employees with AI tools and expect productivity to improve automatically. Existing processes were generally designed around human workflows and older technology, meaning many need to be redesigned before AI can deliver its full benefit. Lerch argued that implementation and change management are becoming some of the biggest challenges. Employees need to understand why workflows are changing, where AI fits into their responsibilities and how their expertise remains essential. Without that engagement, even technically successful systems may struggle to achieve widespread adoption.

The same lesson applies to pharmaceutical executives. Ordering an organisation to use AI without identifying specific problems can create numerous disconnected experiments with little measurable impact. Scientists, clinicians, engineers and data specialists need to work together to identify tasks where AI can genuinely improve outcomes. Productivity may also initially decline. Employees need time to learn new systems, organisations must redesign processes and AI-generated work requires validation. The benefits may only emerge after those initial implementation costs have been absorbed.

The economics of running AI are becoming another consideration. Companies that initially focused almost entirely on model performance are increasingly paying attention to the computing resources consumed by large-scale AI applications. As usage expands across thousands of employees and complex scientific workloads, the cost of inference and token consumption can become material. This introduces another layer to the investment calculation. Pharmaceutical companies need to decide not only whether an AI application works, but whether the value it produces justifies the infrastructure and computing resources required to operate it at scale.

Despite these challenges, the panel suggested that the industry’s direction has changed fundamentally. AI is already producing measurable value in specific areas of pharmaceutical research and clinical development. The next question is whether those improvements can be connected across the entire drug-development chain. If research becomes dramatically faster while clinical trials improve only incrementally, the bottleneck simply moves downstream. The pharmaceutical industry could find itself with more promising compounds than it has patients, trial sites, regulatory capacity or development resources to process.

The larger opportunity is therefore to apply AI across the complete journey from scientific discovery to clinical evidence. Molecule design, translational biology, trial design, patient recruitment, clinical monitoring, data analysis, regulatory preparation and post-market evidence all represent potential areas for improvement. The biggest gains may come when those individual applications begin operating as part of a connected development system rather than separate AI projects.

For pharmaceutical companies, that could fundamentally change the economics of innovation. Reducing development by several months can have significant commercial value. Improving the probability that a candidate entering an expensive clinical programme will ultimately succeed could be considerably more valuable. For patients, the measurement is simpler. The value of faster molecule discovery remains limited until the resulting medicine reaches the people who need it.

AI has begun accelerating the front end of pharmaceutical research. The next stage of the transformation will be determined by whether the industry’s clinical, digital and physical infrastructure can accelerate with it.

Source: CIJ.World Research & Analysis Team

Pharma’s AI Spending Is Rising, but the Real Breakthrough May Be Better Decisions

Artificial intelligence has attracted enormous investment across the pharmaceutical industry, yet the promised productivity revolution has not arrived at the same speed. Drug development remains expensive, clinical programmes remain lengthy and many AI initiatives are still struggling to move beyond demonstrations and pilot projects. That contradiction formed the central argument of a presentation by Kris Kaneta, Chief Product & Innovation Officer at Norstella, during AI4 2026. Kaneta’s message was that the pharmaceutical industry’s biggest AI problem may no longer be access to powerful models, but the inability to convert those models into trusted systems capable of supporting complex decisions involving billions of dollars, years of development and ultimately patients waiting for new treatments.

The timing of the discussion is significant. Pharmaceutical companies have spent heavily on digital technologies, data platforms and artificial intelligence, while the underlying economics of drug development remain difficult. Industry research continues to show rising development costs and long clinical timelines. AI may eventually help address those pressures, but deploying more tools does not automatically make pharmaceutical research more productive. Kaneta characterised the problem as a gap between AI demonstrations and actual decision-making. Pharmaceutical organisations have accumulated pilots, prototypes and proof-of-concept projects that can generate impressive outputs but frequently struggle when they encounter real business processes. The reasons are not necessarily failures of the underlying AI models. A system may work technically while lacking the data, context or workflow integration required to make it useful inside a pharmaceutical company.

That distinction matters because many decisions in life sciences are unusually consequential. Companies must decide which molecules deserve further investment, whether compounds should be developed for additional diseases, how clinical trials should be designed, where studies should be conducted, which investigators should participate and how medicines should ultimately reach patients. A mistake at an early stage can influence years of subsequent investment. Unlike editing a document or generating marketing material, many pharmaceutical decisions cannot simply be reversed once significant capital has been committed. This raises the standard that AI must meet before executives and scientists are willing to rely on it. A plausible answer is not enough. Users need to understand where information came from, whether the underlying evidence is current and whether the system has enough understanding of the specific pharmaceutical problem to produce something useful.

Kaneta argued that trust in these systems rests on several fundamental qualities. Outputs need to be traceable to credible information, they need to remain sufficiently reliable when similar questions are repeated, they must reflect the context of the job being performed, and they ultimately need to influence a real decision or action rather than simply produce an interesting response. That is a much higher threshold than the one required for a successful AI demonstration. A generic language model, for example, can produce a convincing summary of a therapeutic market, but pharmaceutical competitive intelligence requires more than assembling publicly available information. Analysts need to understand whether drugs remain in development, whether trials have been terminated, where regulatory approvals are pending, how competitors’ programmes are changing and how those developments affect a particular company’s strategy. An answer that includes a discontinued product or misses a recently approved medicine may still read perfectly well, yet it could lead to the wrong commercial conclusion.

This is one reason domain-specific data is becoming increasingly valuable in the AI economy. The competitive advantage may gradually shift away from simply possessing access to a large model and towards controlling well-structured, reliable and continuously updated information that gives the model meaningful context. In pharmaceutical markets, that information is spread across numerous areas. Drug pipelines, clinical trials, investigators, regulatory decisions, payer policies, reimbursement, market access, real-world patient data and commercial forecasts may all influence a single strategic decision. Historically, much of this information has existed in separate systems and organisational departments. Business development may maintain different intelligence from market access teams, while clinical development, forecasting and commercial teams use their own databases and analytical processes. Artificial intelligence creates an opportunity to connect these information environments, but only if the underlying data infrastructure is built to support that connection.

Norstella’s response has been to develop Atlas, an agent-based platform designed to combine its pharmaceutical datasets and intelligence across different parts of the drug-development lifecycle. Rather than creating one general AI assistant for every pharmaceutical task, the approach involves developing systems around particular professional roles and decisions. That distinction could become important across enterprise AI more broadly. A competitive intelligence analyst, clinical-trial specialist and market-access professional may all use artificial intelligence, but they do not need the same information or reasoning process. The system therefore needs to understand the objective of the user, not simply retrieve documents containing related words.

Kaneta used the analogy of giving an executive a thousand interns. The additional manpower could theoretically produce enormous output, but only if those workers were given precise instructions, reliable information and a clear definition of what a successful result should look like. Artificial intelligence creates a similar management challenge at vastly greater scale. An organisation can generate huge quantities of analysis, reports and recommendations, but additional output does not automatically mean additional productivity. Without reliable context, businesses risk producing more information without improving the quality or speed of the decisions that matter.

This may help explain part of the apparent productivity paradox surrounding generative AI. Companies can automate individual tasks while the total process remains slow because the underlying decision structure has not changed. A pharmaceutical company might reduce the time required to prepare an analysis from several days to several hours, for example, yet still spend weeks validating the information, moving it between departments and securing approval before acting. The real productivity opportunity therefore lies in redesigning the complete workflow rather than accelerating isolated components. This also changes how companies should evaluate AI investments. The number of employees using an AI platform or the quantity of content generated may say relatively little about its economic value. More relevant measurements include whether clinical trials can be designed more effectively, whether investment decisions are made earlier, whether unsuitable programmes are stopped sooner and whether promising medicines reach patients faster.

The financial implications can be enormous. Drug development requires billions of dollars of capital across research, clinical testing, manufacturing preparation and commercialisation. Improving one major portfolio decision could potentially create greater value than automating thousands of routine administrative tasks. Conversely, an unreliable AI recommendation used in a high-value investment decision could destroy far more value than the technology saves elsewhere. The quality of the data underneath the system therefore becomes an investment issue in its own right. Pharmaceutical companies have accumulated decades of clinical, regulatory and commercial information, but much of it remains fragmented across departments, legacy systems and external providers. Preparing that information for AI can involve substantial expenditure on integration, data governance, metadata, cybersecurity and cloud infrastructure.

The AI transformation of pharmaceutical companies may consequently produce considerable demand for technology infrastructure without immediately appearing as productivity in drug-development statistics. Companies are effectively building a new information architecture while continuing to operate extremely complex existing businesses. The benefits may only become visible once those systems begin influencing decisions across entire development programmes rather than isolated tasks. Another concern is the increasing volume of AI-generated material entering the information environment. As generative systems produce more articles, summaries and analysis, future models may encounter material that was itself generated by other models. Without strong links to original evidence, this creates the possibility of information circulating repeatedly while becoming progressively detached from authoritative sources. That risk is particularly problematic in pharmaceuticals, where outdated or inaccurate information can materially affect investment decisions.

Traceability therefore becomes more than a technical feature. It becomes part of the organisation’s risk-management structure. Executives need to be able to understand why a system reached a conclusion and verify the underlying evidence before committing capital or changing a development strategy. The same principle applies when AI moves towards more autonomous agents. An assistant that produces information remains relatively easy for a human to review, while an agent capable of triggering subsequent actions introduces an additional level of responsibility. The more autonomy these systems receive, the more important it becomes to establish precisely what information they can access, what decisions they can influence and when human approval remains necessary.

Pharmaceutical AI is therefore likely to evolve differently from consumer generative AI. Speed and ease of use remain valuable, but trust, provenance and specialist context can be considerably more important than producing an immediate answer. This favours organisations capable of combining technology with proprietary information and deep sector expertise. It may also reshape competition among pharmaceutical information providers. Companies that historically sold databases, market intelligence and research tools increasingly have the opportunity to transform those assets into the contextual layer supporting AI agents. In this model, the underlying database becomes more valuable because artificial intelligence can interrogate it continuously and connect previously separate areas of information.

The implications extend into pharmaceutical corporate strategy. As AI systems become embedded across research, development and commercial operations, businesses may need to reconsider how departments share information. Traditional organisational silos can directly reduce the effectiveness of AI. A system attempting to evaluate a drug’s commercial opportunity, for example, becomes considerably more useful if it can connect clinical evidence with competitor activity, payer behaviour, regulatory developments and real-world patient information. Breaking down those information barriers can be as difficult as developing the technology itself.

The challenge also affects corporate investment priorities. Pharmaceutical companies may be tempted to fund numerous AI experiments because the cost of creating individual prototypes has fallen dramatically. Yet the more initiatives an organisation launches, the harder it becomes to integrate, govern and evaluate them. A smaller number of applications connected to strategically important decisions may ultimately create more value than hundreds of disconnected AI pilots. The pharmaceutical industry does not have a shortage of artificial intelligence experiments. It has a shortage of AI applications trusted enough to influence decisions that genuinely matter.

Closing that gap could determine whether the industry’s technology investment eventually translates into higher research productivity. The stakes extend beyond corporate efficiency. Longer development timelines mean patients wait longer for medicines, while escalating R&D costs affect which therapies companies are willing to pursue in the first place. If artificial intelligence can help companies identify stronger drug candidates earlier, design better clinical programmes, select more appropriate patients and make faster portfolio decisions, its economic value could ultimately be measured in both capital efficiency and time.

The next phase of pharmaceutical AI may therefore be considerably less visible than the generative AI boom that preceded it. The important innovation will not necessarily be another chatbot or increasingly powerful general-purpose model. It will be the information and decision infrastructure sitting underneath those technologies. For pharmaceutical companies, the central question is shifting from how much AI they are using to whether that AI can be trusted to help make better decisions when billions of dollars and years of drug development are at stake. Until that happens consistently, the industry may continue experiencing the same paradox: increasingly sophisticated artificial intelligence operating inside a drug-development system that remains expensive, slow and difficult to change.

Source: CIJ.World Research & Analysis Team

front page info
LATEST NEWS